Teitur Trophics
Aarhus, DK · Founded 2020 · 25 employees on LinkedIn · 7 known investors
Teitur Trophics is a biotech company developing therapies that target the sortilin family of receptors (SorCS-receptor biology) to activate the brain's natural survival pathways and preserve brain function. Its approach aims to address multiple neurodegenerative diseases by protecting brain cells from dying.
Founders & leadership
Teitur Trophics was founded in 2020 by Simon Mølgaard, Anders Dalby, Mathias Ollendorff, and Simon Glerup.
Investors · 7
Industrifonden✓ verifiedStockholm · $1.1M – $4.3M
P53 Invest✓ verifiedStavanger
Innovestor✓ verifiedFinland
Sound Bioventures✓ verifiedMalmö
Sunstone CapitalreportedFrederiksberg
Also in the syndicate · 2
Innovestor's Life Science FundSunstone Life Science Ventureslead
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AMar 2023 · 3 sources
Sound Bioventures (lead), Sunstone Life Science Ventures (lead), Industrifonden, Innovestor's Life Science Fund, P53 Invest
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Teitur Trophics do?
- Teitur Trophics is a biotech company developing therapies that target the sortilin family of receptors (SorCS-receptor biology) to activate the brain's natural survival pathways and preserve brain function. Its approach aims to address multiple neurodegenerative diseases by protecting brain cells from dying.
- Who founded Teitur Trophics?
- Teitur Trophics was founded by Simon Mølgaard, Anders Dalby, Mathias Ollendorff, Simon Glerup in 2020.
- Who are Teitur Trophics's investors?
- Teitur Trophics's investors include Industrifonden, P53 Invest, Innovestor, Sound Bioventures, Sunstone Capital.
- Where is Teitur Trophics headquartered?
- Teitur Trophics is headquartered in Aarhus, DK.